Clinical trials: Kaposi Sarcoma
Viral Associated Malignancies, Kaposi Sarcoma
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Background: Less toxic and more effective treatments are needed for cancers caused by viruses. These cancers include Hodgkin and non-Hodgkin lymphoma, hepatocellular carcinoma, head and neck cancer, nasopharyngeal carcinoma…
- Conditions
- Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas
- Trial name
- NCT04902443
- Testing
- Pomalidomide, Nivolumab
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Kaposi, HIV Infections
Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma
To determine the safety and effectiveness of combining zidovudine (AZT) and interferon alfa-2a (IFN-A2a) in a treatment for Kaposi's sarcoma (KS) in patients who have AIDS.
- Trial name
- NCT00000687
- Testing
- Interferon alfa-2a, Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diffuse Large B Cell Lymphoma, Kaposi Sarcoma
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
This is a sequential Phase I and IIa study to identify the maximum tolerated dose and to evaluate safety, tolerability, toxicity, pharmacokinetics and pharmacodynamics of the oral sphingosine kinase inhibitor ABC294640…
- Trial name
- ABC-102 (NCT02229981)
- Testing
- ABC294640
- Where
- United States
- Sponsor
- RedHill Biopharma Limited
Kaposi's Sarcoma
Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
The purpose of this study (NAV3-12) is to determine the dissemination and localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with confirmed cutaneous KS.
- Trial name
- NCT02201420
- Testing
- Tc 99m tilmanocept
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Navidea Biopharmaceuticals
Blood Donors, Acquired Immunodeficiency Syndrome
KSHV Infection in Blood Donors From Texas
To determine the seroprevalence of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) in blood donors from Texas. Also to examine the donors' demographic characteristics and to characterize the KSHV using polymerase chain…
- Conditions
- Blood Donors, Acquired Immunodeficiency Syndrome, Blood Transfusion, Herpesvirus, Kaposi Sarcoma-Associated
- Trial name
- NCT00006310
- Sponsor
- The University of Texas Health Science Center at San Antonio
Kaposi Sarcoma, HIV
Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
The purpose of this study is to identify important associations between complete and comprehensive clinical, laboratory, and genomic data derived from patients and tumor specimens, with prospectively recorded clinical outcomes.
- Trial name
- NCT03160183
- Where
- 2 sites in Malawi
- Volunteers
- 157 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Kaposi Sarcoma (KS), HIV
Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe
Kaposi sarcoma (KS) is an AIDS-related cancer and is the most commonly reported cancer in Zimbabwe. If it is found early on, it may be treatable with antiretroviral therapy (ARVs) alone and this will improve general well-being…
- Trial name
- SIKO (NCT01764360)
- Testing
- KS structured clinical care training
- Where
- Zimbabwe
- Volunteers
- 1,024 people
- Sponsor
- University of Colorado, Denver
Kaposi Sarcoma
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Background: Kaposi sarcoma (KS) is a cancer most often seen in people with HIV. It causes lesions. These are usually on the skin but sometimes in the lymph nodes, lungs, and gastrointestinal tract.
- Trial name
- NCT02659930
- Testing
- liposomal doxorubicin, pomalidomide
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Acquired Immunodeficiency Syndrome, Kaposi's Sarcoma
Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
This protocol presents the rationale, 25-year historical review, and methods for multidisciplinary, low-risk studies of individuals referred to the NCI Viral Epidemiology Branch (VEB).
- Conditions
- Acquired Immunodeficiency Syndrome, Kaposi's Sarcoma, Leukemia, Lymphoma
- Trial name
- NCT00001560
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
AIDS-related Kaposi's Sarcoma
A Study of Selumetinib in Patients With Kaposi's Sarcoma
Cancer is a leading cause of death in individuals living with human immunodeficiency virus (HIV), and Kaposi's sarcoma (KS) remains the commonest HIV-associated cancer.
- Trial name
- SCART (NCT01752569)
- Testing
- Selumetinib
- Where
- 6 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Sarcoma, Kaposi, HIV Infections
A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma
To determine the safety and tolerance of interleukin-4 (IL-4) in patients with AIDS-related Kaposi's sarcoma. To determine the effects of IL-4 on tumor growth in patients with AIDS-related Kaposi's sarcoma.
- Trial name
- NCT00000769
- Testing
- Interleukin-4
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Herpesvirus 8
Suppression of Oral HHV8 Shedding With Valganciclovir
The purpose of the study is to use valganciclovir to define the role of antiviral therapy in suppression of HHV-8 shedding in HHV-8 seropositive men.
- Trial name
- NCT00194467
- Testing
- valganciclovir
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Background: Kaposi sarcoma herpesvirus (KSHV)-associated inflammatory cytokine syndrome (KICS) and KSHV-multicentric Castleman disease (MCD) occur in people living with HIV.
- Trial name
- NCT06052618
- Testing
- Pacritinib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
AIDS-Related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
This phase I/II trial studies the side effects and best dose of lenalidomide and to see how well it works in treating patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS).
- Trial name
- NCT01057121
- Testing
- Lenalidomide
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
AIDS-related Kaposi Sarcoma
Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
Randomized phase III trial to compare the effectiveness of paclitaxel with that of doxorubicin in treating patients who have advanced AIDS-related Kaposi's sarcoma.
- Trial name
- NCT00003350
- Testing
- paclitaxel, pegylated liposomal doxorubicin hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- National Cancer Institute (NCI)
Multicentric Castleman s Disease
Natural History of KSHV-Associated Multicentric Castleman s Disease
Background: Kaposi s sarcoma herpes virus (KSHV) causes several kinds of cancer, Kaposi sarcoma (KS), a form of Multicentric Castleman s Disease (MCD) and a type of lymphoma known as Primary Effusion Lymphoma (PEL).
- Trial name
- NCT04968288
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma
RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00450320
- Testing
- sirolimus
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- AIDS Malignancy Consortium
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease
Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis
Background: Some people with human immunodeficiency virus (HIV) are on antiretroviral therapy (ART). Their cells have shown to age faster than expected.
- Conditions
- Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease, Primary Effusion Lymphoma, IL-6 Related KSHV Associated Cytokine Syndrome
- Trial name
- NCT04742387
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)